Celcuity announced updates to its Phase 3 VIKTORIA-2 trial of gedatolisib for HR+/HER2- advanced breast cancer, now including endocrine-sensitive patients alongside endocrine-resistant ones. The trial will assess gedatolisib combined with palbociclib and endocrine therapy, with separate studies and endpoints for each patient group. Additionally, Celcuity is developing a subcutaneous injection form of gedatolisib to improve long-term treatment convenience. These steps aim to broaden treatment options and potentially improve outcomes for about 90,000 women diagnosed annually with this breast cancer subtype.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
Lockheed Martin Ventures, the $1 billion venture capital arm of Lockheed Martin, is expanding into the UK and Europe with a new London office. It plans to invest at least $100 million in defense technology startups to strengthen transatlantic defense...
